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Rheumatoid arthritis – an update for general dental practitioners 
BACKGROUND 
Rheumatoid arthritis (RA) is a common chronic inflammatory autoimmune condition which affects an 
estimated 400,000 UK adults.1 Onset is commonly between 40-50 years old, though can occur at any 
age, with women three times more likely affected than men.1 RA is a common cause of disability; work 
disability increases with age and disease duration.2 RA results in increased healthcare costs and use of 
social security provision, as well as significantly reducing a patient’s quality of life.3,4 
Pathophysiology  
RA is characterised by the production of rheumatoid factor (RF) and anti-citrullinated protein antibody 
(ACPA) against autoantigens commonly expressed within and outside of synovial joints.5 RF is 
produced by B cells in the synovial membrane and is associated with more aggressive joint 
destruction.6 Traditionally, RF was the classic autoantibody in RA, however, ACPAs are now seen as 
being of increased importance as they are more specific and sensitive for RA diagnosis and predict a 
poorer disease course with progressive joint damage.7 RF, ACPA or both are present in 50-80% of 
people with RA.7 
RA has several distinct disease subsets with several inflammatory cascades all resulting in persistent 
synovial inflammation with damage to articular cartilage and underlying bone.7 Key inflammatory 
cytokines in its pathogenesis are tumour necrosis factor- α (TNF-α) and interleukins 1 and 6 (IL-1, IL-
6), which result in the production of proteolytic enzymes and activation of osteoclasts.6-8 
Aetiology  
It is thought RA occurs in response to environmental triggers in genetically susceptible individuals.5 
The most recognised environmental trigger is smoking, which increases levels of the peptidyl arginine 
deiminase (PAD) enzyme responsible for protein citrullination (the conversion of arginine to 
citrulline).9 A recent study identified a clear dose-response relationship between smoking and the risk 
of developing RA.10 The periodontal pathogen Porphyromonas gingivalis has been implicated in the 
aetiology of RA as has, most recently, the gut microbiome.11,12 Other suggested environmental risk 
factors include region of birth, birthweight, breastfeeding and socioeconomic status.13 Genetic factors 
account for 50% of the risk of RA development, with more than 100 loci for genetic susceptibility 
identified to date.14,15 ACPA presence is associated with alleles containing a shared epitope (common 
protein-binding motif) in the HLA-DRB1 locus, and can be detected up to 15 years before RA onset.16,17 
Signs and symptoms  
Common clinical features of RA include a symmetric polyarthritis with joint swelling (particularly in 
the hands and feet).18 Persistent joint inflammation (synovitis) results in bone and cartilage 
destruction which can ultimately lead to deformity, chronic pain and a loss of function.9  Patients can 
experience stiffness upon waking or after prolonged periods of rest.18,19 Systemic inflammation in RA 
can affect the brain (fatigue, reduced cognitive function and cerebrovascular events), liver (elevated 
acute-phase response and anaemia),  heart (myocardial infarction and cardiac failure), lungs 
(inflammatory and fibrotic diseases), exocrine glands (secondary Sjögren’s syndrome), bone 
(osteoporosis) and muscles (sarcopenia).20 In severe RA, subcutaneous nodules and other extra-
articular manifestations (such as vasculitis) can develop.18 
Diagnosis  
In 2010, the European League Against Rheumatism (EULAR) and the American College of 
Rheumatology (ACR) jointly released new classification criteria for RA to assist rheumatologists with 
the diagnosis of newly-presenting patients.21 This assesses joint involvement, autoantibody status, 
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acute-phase reactants and symptom duration.7 Early diagnosis and initiation of intensive treatment 
prevents joint damage, and greatly improves functional outcome and morbidity for patients.18 
Clinical assessment  
Disease activity is often assessed using combined indices such as the Disease Activity Score based on 
the 28 joint count (DAS-28) which assesses joints in the hands, arms and knees for swelling and 
tenderness; measures the erythrocyte sedimentation rate (an inflammatory marker) and the patient’s 
global assessment (a visual analogue scale-based score the patient gives for how RA is affecting them 
overall at that time).6 The Simplified Disease Activity Index (SDAI) or the Clinical Disease Activity Index 
(CDAI) are alternatives.6 X-rays, ultrasound and magnetic resonance imaging are all used to assess 
structural changes in the joints.6  
Medical management 
The aim of drug therapy is to reduce symptoms and suppress inflammation, thereby limiting joint 
damage and disability.22 Currently, it is recommended to follow a ‘treat-to-target’ strategy which 
involves initiating intensive drug therapy immediately after diagnosis and escalating this, guided by 
disease activity assessment, until clinical remission or low disease activity is achieved.20,22 Disease-
modifying anti-rheumatic drugs (DMARDs) are the primary treatment used as they reduce pain and 
swelling of the joints, lower levels of acute-phase inflammatory markers, limit progressive joint 
damage and improve function.7 The first DMARD usually prescribed is methotrexate (sulfasalazine or 
leflunomide can be given if methotrexate is contraindicated).7 DMARDs can be used in combination 
to be more effective.23  
Conventional DMARDs modify the whole immune system, whereas biologic DMARDs target specific 
components within the inflammatory pathway.6 Biologic DMARDs are given to patients with 
persistently active disease, and are highly effective.22 They are usually prescribed for use in 
combination with methotrexate, as it is thought that this both reduces antibody formation to the 
biologic agent and increases its efficacy.7 Smoking reduces the efficacy of conventional DMARDs and 
smokers are more likely to fail on biologic therapies.24 
In RA, the pain response appears to be heightened; analgesics and non-steroidal anti-inflammatory 
drugs (NSAIDs) can be used for additional symptom control.7,25 Due to unfavourable side-effects, 
corticosteroid use is restricted to bridging therapy during acute flares of symptoms (‘flare-ups’) whilst 
awaiting DMARDs to reach full efficacy.7 Intra-articular injections are highly effective for disease 
suppression in individual active joints.7 New biologic DMARDs are currently in development, whilst 
biosimilar drugs and novel small molecule agents have come onto the market.6,22,26 The long-term 
effect of these drugs in clinical practice is yet to be determined. See Table 1. for a list of the most 
common drugs currently used to manage RA. 
Having RA increases the risk of infections and this is raised further with the use of biologics.6 Biologic 
DMARDs have approximately a 30% increased chance of serious infection (e.g. tuberculosis) over 
conventional DMARD use, with this risk at its highest during the first six months of therapy.27,28 Other 
infection risks are bacterial (e.g. sepsis, abscesses and cellulitis), fungal (e.g. candidosis) and viral (e.g. 
shingles).7,29 Although there has been speculation about an increased risk of developing cancer with 
biologics use, a recent systematic review has shown this to be little or none.30 In future, it may be 
possible to taper biologic DMARDs in select patients whose RA is in remission.31  
Improved management of RA over the past two decades has resulted in a decline in its severity with 
less inflammatory biomarkers, extra-articular manifestations, hospital admissions and joint 
replacements.7 As better therapies have resulted in the reduction or absence of deformities, RA 
patients can appear quite ‘normal’.32 For effective RA management, adjunct non-pharmacologic 
interventions are also advised (such as patient education, physiotherapy, occupational therapy, foot 
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care and psychological support) which are delivered by a multidisciplinary team of healthcare 
professionals.33 
Co-morbidities  
Co-morbid conditions can be coincidental (with some already present at RA diagnosis), reflective of 
RA or its treatment.34 RA patients have excess mortality from cardiovascular disease (CVD), but it 
remains unclear whether cardiovascular events are caused by inflammation associated with RA rather 
than traditional cardiac risk factors (such as hypertension, dyslipidemia and cigarette smoking).35,36 
DMARDs are associated with a decreased risk of all cardiovascular events but this is increased with 
use of NSAIDs and corticosteroids.37  
After CVD, the second most common cause of mortality in RA is from cancer, particularly lymphoma 
and lung cancer.38,39 Patients with RA are more likely to develop skin cancer (non-melanoma and 
possibly melanoma) than the general population, and this risk may be increased by DMARD use.40-42 
RA patients have an increased risk of osteoporosis and resultant bone fractures linked to age, disease 
duration and steroid therapy.38 Other co-morbidities include anaemia, depression, fibromyalgia, 
interstitial lung disease, Sjögren’s syndrome, periodontal disease, diabetes mellitus and 
obesity.7,34,38,39,43-46  
It was previously reported that RA patients die prematurely from one or more comorbid diseases.47 
However, a recent study found that people who had RA onset after 2000, no longer have an increased 
risk of mortality compared to the general population.48 This is likely due to improved treatments and 
tighter disease control over the last two decades. Overall, comorbidities increase disability levels, 
reduce a patient’s quality of life, makes patient management more complex and increases the 
economic burden of disease.34,38 
 
ORAL HEALTH 
Oral health complications due to RA and its treatments can cause additional problems for patients. A 
recent study found that approximately 30% of RA patients were taking additional analgesics 
specifically for oral pain.49 Due to their immunosuppressive effects, RA medications can promote 
periodontitis, candidosis and oral ulceration aided by a lack of saliva.50 The three main oral conditions 
associated with RA are discussed below: 
Periodontal disease 
Periodontal disease (PD) is a chronic inflammatory condition which leads to destruction of the 
periodontal ligament and alveolar bone, and can result in tooth loss.51 PD is caused by the presence 
of pathogenic gram-negative anaerobic bacteria within the biofilm attached to the sub-gingival tooth 
surface.9 Porphyromonas gingivalis (Pg) is the main pathogen in PD.9 Its virulence combined with an 
intense host immune response is thought to contribute to the severity of the disease.9  
People with RA are almost twice as likely to have PD than those without.52 RA patients with severe PD 
have significantly higher DAS-28 scores than those with moderate or no periodontitis, and PD is 
associated with increased radiographic joint damage.53,54 These data strongly suggest an association 
between RA and PD/tooth loss. This association is independent of common risk factors such as 
smoking, alcohol intake, socioeconomic background and poor oral hygiene.55   
RA and PD are both chronic inflammatory diseases. Both conditions feature excessive destruction of 
collagen-rich tissues: in RA these are bone, cartilage and other periarticular tissues; in PD these are 
alveolar bone, periodontal ligament and gingiva.56 Alveolar bone loss in PD results from the activation 




PD may be involved in the initiation and/or maintenance of systemic inflammation in RA.9 The level of 
Pg antibodies has been found to positively correlate with levels of ACPA in circulation in RA.57 Pg  is 
the only bacterium known to express a PAD enzyme, which can cause the citrullination of bacterial 
and host proteins.58 This is thought to cause the body to produce ACPA, which drives the autoimmune 
response in RA.58 PAD enzymes, citrullinated proteins and ACPA have all been found in inflamed 
gingiva.59,60 Antibodies to the periodontal pathogens Pg and Prevotella intermedia have been found in 
the serum and synovial fluid of patients whose RA is active.61,62 
Effective control of PD for RA patients is important to reduce both local and systemic inflammation, 
and the likelihood of bacteremia.63 Persistent periodontitis can also reduce the effectiveness of TNF 
inhibitors.64 Short-term clinical trials have demonstrated that non-surgical periodontal therapy in RA 
patients with PD, can decrease RA disease activity and systemic inflammation.65-67 Reduction in disease 
activity may be due to less inflammatory products, bacteria and endotoxins in the bloodstream after 
periodontal treatment, thereby reducing the exposure of joints to these products.68,69 Longer-term 
clinical trials are currently in progress to find out whether non-surgical periodontal treatment can lead 
to an improvement in clinical outcomes and quality of life for patients with active RA.70 A recent 
systematic review also highlighted the importance of smoking cessation, which results in improved 
outcomes for non-surgical periodontal therapy.71  
Temporomandibular dysfunction 
The temporomandibular joint (TMJ) is used up to 2000 times a day for chewing and speaking, making 
it one of the most frequently used synovial joints in the body.72 People with RA have a higher frequency 
and greater severity of temporomandibular dysfunction (TMD) than the normal population.73 The 
estimated prevalence of TMJ symptoms in adults with RA is between 5-86% (depending on diagnostic 
criteria, assessment methods and the population studied) with clinical involvement of the TMJ seen 
in about 50% of cases.73,74 In a 2013 survey of RA outpatients at a tertiary center, 45.8% had problems 
with chewing (with 40.3% having to adjust their diet accordingly), 30.6% felt discomfort when eating 
and 36.1% took medication to relieve oral pain.49 
RA patients with TMD may present with pain, difficulty with opening the mouth, ‘locking’ of the jaw, 
tenderness of the TMJ/masticatory muscles, and joint sounds.73,75 The most frequent joint sound is 
clicking, followed by crepitus (which indicates TMJ degeneration but may be seen less often due to 
improved RA medication).76 It is thought that pain in TMD is associated with RA disease activity, and 
impairment in the range of motion and function of the TMJ are more likely due to degeneration of the 
joint.73 Patients may also report associated symptoms such as ear pain/stuffiness, tinnitus, dizziness, 
headache and neck pain.77 It is important to note that the TMJ may already be affected by RA in 
patients who do not yet report TMD symptoms.78 
Clinical signs of TMJ involvement include swelling, reduced range of motion and/or deviation of the 
mandible to the affected side.75 Imaging shows condylar resorption with a resultant shortening of the 
mandibular ramus-condyle unit and possibly a reduced joint space.77 Cone-beam computed 
tomography (CBCT) imaging is best for showing the extent of condylar damage from RA, particularly 
in the early stages, and involves a lower radiation dose than conventional CT scans.79 There is a positive 
correlation between the duration and severity of RA, and the degree of TMJ involvement.78 Ankylosis 
of the TMJ is uncommon and occurs late in the disease course.74 If ankylosis or collapse of the TMJ 
occurs, joint replacement may become necessary.74 This has been shown to have good long-term 
outcomes for patients with inflammatory arthritis.80 TMD management in RA needs to involve the 
patient’s rheumatologist and an oral & maxillofacial surgeon with an interest in TMJ diseases.74 
Juvenile Idiopathic Arthritis (JIA), also known as Juvenile Rheumatoid Arthritis, affects around 12,000 
children in the UK.81 The reported prevalence of TMJ arthritis in JIA ranges from 17 to 87%.82 Restricted 
mouth opening is the most frequent clinical finding (28% of patients) followed by masticatory muscle 
tenderness, deviation of the mandible on opening, TMJ tenderness and joint sounds.82 TMJ arthritis in 
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children can cause a disturbance of mandibular growth and evident alterations in craniofacial 
morphology and occlusion; features typically seen include an increased profile convexity, a steeper 
mandibular plane angle, mandibular micrognathia and retrognathia.83 
Inflammation occurs during the active phase of JIA, which ultimately causes resorption of the 
condyles.82 Damage to the condyles may be present early on in JIA and progress, even when clinical 
symptoms and signs are absent.82 The current gold standard method of imaging in JIA to detect early 
arthritic changes in the TMJ is magnetic resonance imaging (MRI) with contrast.84 Patients with JIA 
should have regular imaging of the TMJ and evaluation by an orthodontist, even in the absence of TMD 
signs and symptoms.82  
Lastly, it is important to note that some patients with RA/JIA will have TMD that is unrelated to their 
inflammatory arthritis.  
Salivary gland dysfunction 
Sjögren’s syndrome (SS) is a chronic autoimmune condition that is characterised by the sicca 
symptoms xerophthalmia and xerostomia, caused by inflammation leading to dysfunction of the 
lacrimal and salivary glands.85 It can occur alone (primary form) or secondary to other systemic 
autoimmune diseases such as RA.86  The estimated prevalence of sicca symptoms in RA patients ranges 
between 30-50%.86 
RA patients with SS have reduced salivary flow and altered saliva composition (due to destruction and 
dysfunction of the salivary glands).87 This reduces the buffering and antimicrobial properties of saliva 
causing an increased likelihood of caries.88 The subjective experience of xerostomia in SS is not 
dependent on the total quantity of saliva (salivary flow) but rather the quantity and quality of specific 
components within it (called mucins) which affect its ability to retain water.87 Up to 70% of salivary 
mucins are produced by the minor salivary glands and overall they produce 10% of saliva.89 Therefore, 
currently available treatments aimed solely at increasing salivary flow may not be sufficient to provide 
relief for SS patients. 
Xerostomia can affect the oral cavity in many ways (see Table 2). Besides SS, a dry mouth can also be 
caused by medications taken by RA patients (see Table 1.). It is important to note that xerostomia may 
be reported by patients before obvious signs of hyposalivation are visible in the mouth.87 If a patient 
presents with a dry mouth and also complains of dry eyes, it is worth writing to their general medical 
practitioner (GP), or rheumatologist if they have a known rheumatic disorder, for further investigation. 
 
DENTAL MANAGEMENT  
General considerations 
Most RA patients can be successfully managed at the dental practice with some minor adjustments – 
see Table 3. for suggestions. Chronic inflammation of the cervical spine in RA can result in neck 
instability, which can cause neurological symptoms and in rare cases be fatal.92 It is therefore 
important that a patient’s head and neck are well supported during dental treatment. Suspected 
cervical instability should also be discussed with the patient’s rheumatologist. 
Due to pain, impaired hand function and fatigue; RA patients may find it difficult and lack the 
motivation to follow a good oral hygiene regime (leading to further unfavourable outcomes).54,55,95,96 
Good oral hygiene is the cornerstone for dental management of these patients, and aids should be 
recommended to making brushing and interdental cleaning easier for this population with poor grip 
and dexterity. Resources on suitable aids and adaptations are available.93,95 See Table 4. for a summary 
of management of common RA-associated dental problems. If a patient is having recurrent problems 
due to their RA or medication, please discuss this with their rheumatologist or GP. 
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Concurrent medications  
As for any patient, it is important to take and keep updated a thorough medical/surgical history with 
a full medication list. Be aware of drug interactions when prescribing (particularly antibiotics); if in 
doubt consult the British National Formulary.101 If prescribing NSAIDs, check what the patient is 
already taking and assess toxicity risk.94 Some RA patients take oral bisphosphonates for the 
prevention or treatment of osteoporosis; therefore, there is a small risk (estimated at 0.5%) of 
osteonecrosis of the jaw following dentoalveolar surgery.102 This risk can be increased with 
concomitant use of corticosteroids, and in some cases bisphosphonates may need to be stopped at 
least two months prior to surgery.102 Biologic DMARDs should be stopped much before major surgical 
procedures (according to the half-life of drug) so as not to increase infection risk.6 Conventional 
DMARDs may need to be stopped prior to procedures which last over an hour and it is recommended 
corticosteroid exposure be minimised prior to surgery.103 Therefore it is important to consult with the 
patient’s rheumatologist well in advance of any planned invasive procedures and to follow up the 
patient postoperatively. 
Antibiotic and steroid cover 
The National Institute for Health and Care Excellence’s recently updated guidance is that patients 
considered at high risk of infective endocarditis do not routinely require antibiotic prophylaxis for 
dental procedures, though this may be appropriate in individual cases.104 If in doubt, consult with the 
patient’s cardiologist.  
Latest guidelines from the British Society of Rheumatology state that pre-operative increase in steroid 
dose, for adrenal crisis prevention, is no longer routinely required.103 However, if a patient shows signs 
of adrenal crisis (vomiting, abdominal pain, syncope, low blood pressure, hypoglycemia, confusion) 
during a procedure, seek immediate emergency medical attention.94 
Co-morbidity detection 
Dentists should be aware of the potential co-morbidities with RA and refer patients on to an 
appropriate medical professional for further investigation (copying in the patient’s rheumatologist and 
GP) if they detect anything of concern. 
CONCLUSION 
RA is a multi-faceted disease which can be complex to manage as co-morbid conditions are frequently 
present. Dental complications can arise associated with RA or its treatment. It is important that the 
dental team are aware of them so these patients can be successfully managed in general dental 
practice, with early intervention to prevent a further decline in their quality of life. Simple adjustments 
can be made to make dental visits more comfortable for patients with this long-term condition. 
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Table 1. Drugs commonly used in RA management.6,22 
Drug class Generic names 















Biologic DMARDs Adalimumab                  
Etanercept                      
Infliximab                           TNF inhibitors 
Certolizumab pegol     
Golimumab                   
Rituximab                       – B-cell depletor 
Abatacept                       – T-cell costimulation inhibitor 
Tocilizumab                    – IL-6 inhibitor 
Small molecule agents  Tofacitinib                    – JAK inhibitor 
[More to be licensed] 
NSAIDs = Non-steroidal anti-inflammatory drugs. DMARDs = Disease-modifying anti-rheumatic drugs. TNF = Tumour necrosis 







Table 2. Oral signs and symptoms of Sjögren’s Syndrome.75,88,90,91 
Signs Symptoms 
 Enlarged parotid glands  
 Absence of saliva pooling in floor of mouth 
 Dry/cracked oral mucosa and lips 
 Mouth sores 
 Increased caries incidence (especially cervical) 
 Increased dental erosion 
 Erythematous cobblestoned/fissured tongue 
 Atrophy of filiform papillae 
 Coated tongue (‘black hairy tongue’) 
 Candidosis 
 Halitosis 
 Difficulty with denture retention 
 Soreness 
 Burning 
 Loss of/altered taste sensation 
 Difficulty with eating 
 Difficulty with swallowing 
 Difficulty with speaking 





Table 3. Suggestions to make dental visits more comfortable for RA patients.93,94 
Before treatment  Organise appointments at times more suitable for the patient’s condition. 
e.g. if they experience morning stiffness, schedule visits for the afternoon. 
 Make shorter, more frequent appointments rather than lengthy visits 
where patients can experience stiffness in the dental chair. 
 Book a treatment room with step-free access. 
During treatment  Adjust the dental chair and headrest to a comfortable position, as RA 
patients can get considerable neck pain and stiffness during treatment. 
 Offer the patient a small pillow or allow them to bring their own. 
 Allow the patient to rest and move their jaw periodically during treatment 
to prevent pain, fatigue and stiffness from keeping their jaw open for 
prolonged periods. 
 Reassure the patient that they can ask to take a break at any time. 









Table 4. Summary of suggested management for RA-associated dental problems.74,75,77,88,90,91,93-95,97-100 
Dental problem Management 
Periodontal disease  More frequent dental/hygiene visits 
 Regular scaling and root planing (no adjuncts necessary) 
 Oral hygiene instruction – recommend electric toothbrushes and 
interdental cleaning aids with wider handles 
 Smoking cessation advice and support 
 Refer to a periodontist if necessary 
Temporomandibular  
dysfunction  
 Jaw rest 
 Warm compress application 
 Physiotherapy 
 Soft food diet  
 Short-term NSAID use (topical or systemic) 
 Occlusal splint (soft or hard) wear at night time  
 Biobehavioural therapy 
 Elimination of unhelpful habits e.g. nail biting, wide yawning 
 Discuss with patient’s rheumatologist/GP if TMJ arthritis suspected 




 More frequent dental visits 
 Medication review 
 Advise to keep hydrated with regular sipping of water 
 Smoking cessation advice 
 Chew sugar-free gum or lozenges regularly (if no TMJ problems) 
 Oral hygiene instruction 
 Pit and fissure seal teeth 
 Fluoride varnish, prescription-strength toothpaste or mouthwash 
 Use of non-fluoride remineralising agents e.g. calcium phosphate rinse 
 Chlorhexidine varnish, gel or mouth rinse 
 Advise to reduce sugar/acid intake and frequency 
 Salivary replacement (gels, mouth rinses, toothpastes, lozenges) 
 Advise patient to use a humidifier, particularly when sleeping 
 Discuss with patient’s rheumatologist/GP 
 Prescribe salivary stimulants e.g. pilocarpine  
 Refer to oral medicine if necessary 
 Refer to GP/rheumatologist if an undiagnosed underlying rheumatic 
disease is suspected 
Oral candidosis/ 
Angular cheilitis  
 Prescribe topical or systemic antifungals  
 Discourage denture wear at night 
 Encourage good denture hygiene 
Oral ulceration  Check patient is taking medication (especially methotrexate) at the 
prescribed dose and interval 
 Prescribe benzydamine mouthwash/oromucosal spray 
 Urgent referral to oral medicine if ulcers are longstanding (> 3 weeks) 
or suspicious 
NSAID = Non-steroidal anti-inflammatory drug. GP = General medical practitioner. TMJ = Temporomandibular joint. 
 
 
